October 4, 2018
FDA: Endo Pharmaceuticals recalls two lots of Robaxin
Editor's Note
The Food & Drug Administration on September 28 announced the recall by Endo Pharmaceuticals Inc of two lots of Robaxin 750 mg tablets because of incorrect dosing information on the label.
Robaxin contains methocarbamol, which is used as a muscle relaxant. Patients who follow the incorrect dosing information may experience significant drowsiness and dizziness or they may have an overdose that results in seizures, coma, or death.
To date, the company has not received any reports of adverse events related to the recall.
Free Daily News
- Study finds workforce readiness gap in new nurses
- Joint replacement manufacturer recalls products after FDA packaging warning
- Gene-edited pig kidney, heart pump combined in transplant surgery milestone
- Catheter sterility concerns prompt Class 1 FDA recall for surgery trays
- Large amounts of personal data possibly stolen in Change Healthcare cyberattack
- AI model helps predict patient decline, drive collaborative care
- One patient’s recovery highlights benefits of outpatient endoscopic spine surgery
- Getting ready for the OAS CAHPS Survey 2025 requirement
- Contribute to perioperative education with the 2024 OR Manager Salary/Career Survey
- Supply chain stability improves, but threats remain
© Access Intelligence, LLC. All rights reserved. | Privacy Policy | Diversity, Equity, Inclusion & Belonging